Ferring Pharmac Patent-Cliff Exposure & CMS Drug Spending Portfolio

Ferring Pharmac (US): 3 reconciled FDA prescription therapies, $4.3M 2024 CMS Part D & Medicaid spend, and $60,000 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$4.3M
2024 Medicare Part D Spend$3.5M
2024 Medicaid Spend$835K
California HCAI SB 17 FilingsSpecialty launch notice ($60,000 intro WAC)